Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors

European Journal of Pharmacology

Volumn 366, Issue 2-3, 1999, Pages 293-300

  Perachon, Sylvie ^a   Schwartz, Jean Charles ^a   Sokoloff, Pierre ^a  

^a CENTRE PAUL BROCA   (France)

Author keywords

Bromocriptine; Parkinson's disease; Pergolide; Pramipexole; Recombinant receptor; Ropinirole

Indexed keywords

BROMOCRIPTINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPARKINSON AGENTS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CYCLIC AMP; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG EVALUATION; HUMANS; HYBRID CELLS; MITOSIS; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECOMBINANT FUSION PROTEINS; SULPIRIDE; TUMOR CELLS, CULTURED;

EID: 0033026623     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00896-6     Document Type: Article

References (49)

1. Adler C.H., Sethi K.D., Hauser R.A., Davis T.L., Hammerstad J.P., Bertoni J., Taylor R.L., Sanchez-Ramos J., O'Brien C.F. Ropinirole for the treatment of early Parkinson's disease. Neurology. 49:1997;393-399.
2. 1 receptors in vivo Life Sci. 38:1986;1507-1514.
3. 3 receptor as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA. 94:1997;3363-3367.
4. 2 receptor mRNA. Brain Res. 564:1991;203-219.
5. Brooks D.J., Torjanski N., Burn D.J. Ropinirole in the symptomatic treatment of Parkinson's disease. J. Neural Transm. 45:1995;231-238.
6. 1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res. 730:1996;17-31.
7. Calne D.B., Teychenne P.F., Leigh P.N., Bamji A.N., Greenacre J.K. Treatment of parkinsonism with bromocriptine. Lancet. 2(7893):1974;1355-1356.
8. 2 dopamine receptor classification and its functional implications. Synapse. 1:1987;347-388.
9. 3 receptor. Neuroscience. 65:1995;731-745.
10. 3 receptor mRNA in proliferative zones during embryonic development of the rat brain. J. Neurosci. 17:1997;4282-4292.
11. 1-containing neurons. J. Neurosci. 15:1995;8167-8176.
12. Gianutsos G., Palmeri J.L. Effects of three dopamine agonists on cage climbing behavior. Psychopharmacology. 79:1983;329-331.
13. 3 receptor: opposite and synergistic interactions with cyclic AMP. J. Neurochem. 67:1997;1-9.
14. Group P.S. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study. JAMA. 278:1997;125-130.
15. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International pramipexole-bromocriptine study group. Neurology. 49:1997;1060-1065.
16. 3H ]PD 128907 Psychopharmacology. 128:1996;240-247.
17. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18:1966;925-964.
18. Hubble J.P., Koller W.C., Cutler N.R., Sramek J.J., Friedman J., Goetz C., Ranhosky A., Korts D., Elvin A. Pramipexole in patients with early Parkinson's disease. Clin. Pharmacol. 18:1995;338-347.
19. 2 synergism and receptor supersensitivity. Proc. Natl. Acad. Sci. USA. 90:1993;7451-7455.
20. Langtry H.D., Clissold S.P. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs. 39:1990;491-506.
21. Leff P. The two-state model of receptor activation. Trends Pharmacol. Sci. 16:1995;89-97.
22. 3H -antagonists. Evidence for the presence of high and low affinity agonist-binding states Mol. Pharmacol. 27:1985;171-183.
23. 3H ]-hydroxy-N,N-di-n-propyl-2-aminotetralin Proc. Natl. Acad. Sci. USA. 89:1992;8155-8159.
24. 2 receptor binding in the rat brain and pituitary. An in situ hybridization receptor autoradiographic analysis. J. Neurosci. 10:1990;2587-2601.
25. Marsden, C.D., Parkes, J.D., Quinn, N., 1982. Fluctuations in disability in Parkinson's disease: clinical aspects. In: Marsden, C.D., Fahn, S. (Eds.), Movement Disorders. Butterworth Scientific, New York, pp. 96-122.
26. 125I ]iodosulpride, a highly selective ligand Science. 228:1985;752-755.
27. 5 dopamine receptor mRNA in the rat brain. Neurosci. Lett. 145:1992;209-212.
28. Mizuno Y., Kondo T., Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology. 45:1995;S13-S21.
29. 2 receptor activation. Psychopharmacology. 94:1988;263-266.
30. 35S ]Guanosine-5′-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents J. Pharmacol. Exp. Ther. 282:1997;181-191.
31. 2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J. Neurosci. 12:1992;3729.
32. 1b receptor. Eur. J. Pharmacol. 267:1994;85-93.
33. Pezzoli G., Martignoni E., Pacchetti C., Angeleri V., Lamberti P., Muratorio A., Bonuccelli U., De Mari M., Foschi N., Cossutta E.et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology. 45:1995.
34. 3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 268:1994;129-139.
35. 3H ]NGD 94-1 J. Pharmacol. Exp. Ther. 282:1997;1020-1027.
36. 3 receptors in rat ventral striatum: opposite and synergistic functional interactions. Eur. J. Neurosci. 10:1998;1676-1686.
37. 2 dopamine agonists on turning behaviour in rats. Brain Res. 384:1986;387-390.
38. 2 dopamine receptors involved in locomotor activity of supersensitive mice. Eur. J. Pharmacol. 148:1988;419-426.
39. 2 receptors. NeuroReport. 6:1995;329-332.
40. 2 receptor. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 225:1992;331-337.
41. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res., in press.
42. 1A receptor. Proc. Natl. Acad. Sci. USA. 88:1991;7491-7495.
43. Urwyler S. Affinity shifts induced by cations do not reliably predict the agonistic or antagonistic nature of ligands at brain dopamine receptors. J. Neurochem. 49:1987;1415-1420.
44. 2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned Parkinsonian Rhesus monkeys. Mov. Disorders. 9:1994;664-672.
45. Vitti R.J., Ahlskop J.E. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs. 5:1996;369-388.
46. Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J. Neural Transm. (P-D Sect.). 3:1991;151-201.
47. 2-like dopamine receptor systems. In: Niznik, H.B. (Eds.), Dopamine Receptors and Transporters. Pharmacology, Structure, and Function. Marcel Dekker, New York, pp. 511-540.
48. 2 agonists effects. Science. 236:1987;719-722.
49. 2-dopamine receptor in the anterior pituitary gland. Mol. Pharmacol. 26:1984;214-227.